Breaking America's Dependence on Imported Molybdenum  by Einstein, Andrew J.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 3 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 8 . 1 0 . 0 0 8B U S I N E S S A N D A D V O C A C Y
Breaking America’s Dependence on
Imported Molybdenum
Andrew J. Einstein, MD, PHD, FACC
Approximately 9 million nuclear cardiology studies performed each year in the U.S. use technetium-
99m, which is produced from the decay of molybdenum-99. The fragility of the worldwide technetium-
99m supply chain has been underscored by current shortages caused by an unplanned shutdown of
Europe’s largest reactor. The majority of the U.S. supply derives from a reactor in Canada that is nearing
the end of its lifespan and whose planned replacements have been cancelled recently. In this article, the
clinical importance of technetium-99m and our tenuous dependence on the foreign supply of
molybdenum are addressed, along with potential measures that may be taken to ensure that America’ssupply chain remains unbroken.W
ith gasoline prices reaching
record highs last year, Americans
have become keenly aware of our
reliance on foreign oil. In hindsight,
earlier attention to developing alternative en-
ergy sources may have averted the conse-
quences of this dependence.
Lost amid the news about oil prices is
another type of energy crisis in the making.
The recent announcement by an obscure state-
controlled Canadian company that it had dis-
continued plans to develop 2 nuclear reactors
has garnered virtually no attention, but it
should be of great concern to all, and to
cardiologists in particular. This announcement
sets the stage for an impending crisis in our
nation’s radioisotope supply, leading to difficult
triage decisions, delayed procedures, and worse
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indicated imaging will be denied, deferred, or
performed suboptimally. Thankfully, unlike for
oil, this is a situation in which we still have
time to act before paying the serious conse-
quences of foreign dependence.
Roughly 40 million nuclear medicine proce-
dures are performed worldwide each year, with
one-half of these in the U.S. The most com-
monly performed nuclear medicine test, ac-
counting for one-half of all nuclear medicine
procedures, is the myocardial perfusion imag-
ing study. In the U.S., approximately 9 million
such nuclear stress tests are performed each
year (1).
Although there are many radioisotopes used
in nuclear medicine, the field’s workhorse is
technetium-99m (Tc-99m), which is incorpo-
rated into over 30 different radiopharmaceuti-
cals. Approximately 4 of 5 patients undergoing
nuclear medicine studies receive a Tc-99m–
based radiopharmaceutical (2), including 97%
of patients undergoing nuclear stress testing
(1). For myocardial perfusion imaging, Tc-
99m–labeled perfusion tracers offer several ad-
vantages over their common alternative,
thallium-201 (Tl-201), which is cyclotron pro-
duced and has witnessed a steady decline in use
during recent years (1). Attenuation of photons
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370as a function of soft-tissue depth is a
potential limitation of Tl-201 in pa-
tients with large body habitus. In addi-
tion, because of the long physical half-
life of Tl-201, the amount of thallium
administered to a patient is confined by
its radiation burden (3). Although
there are alternative myocardial perfu-
sion tracers, such as rubidium-82 and
N-13 ammonia, imaging these perfu-
sion tracers requires positron emission
tomography, which is not as readily
available as the single-photon emission
tomography cameras used for imaging
Tc-99m and Tl-201.
Tc-99m is produced from the decay
of molybdenum-99 (Mo-99). Because
the half-life of Mo-99 is only 66 h, it
cannot be stockpiled and, therefore, the
medical benefits of Tc-99m are depen-
dent on a reliable and continuous sup-
ply chain of Mo-99. More than 90% of
the world’s supply of Mo-99 derives
from the irradiation of uranium targets
at 5 nuclear reactors in Canada, Bel-
gium, the Netherlands, France, and
South Africa (Table 1) (2). There has
not been a U.S. source capable of pro-
ducing significant amounts of Mo-99
in 2 decades (4,5).
The majority of the Mo-99 used in
this country is imported from Canada,
where it is produced at a reactor in
Chalk River, Ontario, before process-
ing. This National Research Universal
(NRU) reactor is now more than 50
years old. It was slated to be replaced
Table 1. Major Worldwide Reactors Producing M
Reactor Lo
National Research Universal (NRU) Chalk Riv
High Flux Reactor (HFR) Petten, th
South African Fundamental
Atomic Reactor Installation-1
(SAFARI-1)
Pelindaba
Belgian Reactor-2 (BR2) Mol, Belg
OSIRIS Saclay, Fr
*Through government’s solely owned entity or public utility.
a full week the maximum load of targets. Adapted from Bo
IRE  Institut National des Radioéléments, Belgium; NTPwith 2 new reactors, referred to asMAPLE (Multipurpose Applied Phys-
ics Lattice Experiment) reactors. These
completed construction in 2000 but
were never commissioned for use. After
8 years of design flaws, budget over-
runs, and safety concerns, Atomic En-
ergy of Canada Limited cancelled the
program in May 2008, deeming the
new reactors not feasible to operate,
and the Canadian government subse-
quently announced that the decision is
final.
This leaves America’s Mo-99 supply
dependent on the old NRU reactor,
which has been subject to multiple shut-
downs. A planned 4-day maintenance
shutdown in November 2007 was ex-
tended to 4 weeks as the result of safety
concerns, leading to molybdenum short-
ages and the intervention of Prime Min-
ister Stephen Harper to restart produc-
tion before completion of a mandated
safety upgrade. A current industry esti-
mate is that the NRU, which was origi-
nally scheduled to close in 2005, could
last until 2014 (6). This continuation
would require an extension of the current
operating license, which expires in 2011,
and further safety concerns could arise at
reinspection.
After the NRU ceases operations,
the 4 other high-capacity reactors could
not ramp up production to meet world-
wide molybdenum demand for a
stretch of more than a few weeks.
Moreover, each is at least 40 years old,
and transport of molybdenum from
9 and Their Distributors
ion Owner*
Operatio
(Days/Yea
anada Canada 315
etherlands European Union 290
uth Africa South Africa 315
Belgium 115
France 220
ata are representative for 2004. Capacity Mo-99 production is t
t al (2).
uclear Technology Products, owned by South Africa.these facilities across the Atlantic isassociated with sizable radioactive de-
cay, requiring more isotope at greater
cost. The fragility of the worldwide
molybdenum supply has been further
underscored by the temporary closure
in August 2008 of each of the 5 major
reactors producing Mo-99 (7). Four
reactors, including the NRU, were
down for scheduled maintenance, and
the reactor in the Netherlands that
produces the majority of Europe’s mo-
lybdenum and is the second largest
source for the U.S. was down as the
result of a leak into its cooling system
caused by corrosion of its pipe work (8).
This situation, which at the time of this
writing is expected to last until Febru-
ary 2009, has led to a decrease in the
supply of Tc-99m generators available
in the U.S. In Europe, which is more
dependent on the Dutch reactor, more
pronounced shortages and rationing
have occurred, a harbinger for what we
can expect here post-NRU unless a
good solution is in place.
The long-term solution to the U.S.
molybdenum needs is a domestic
source. This solution has been recog-
nized by professional societies for more
than a decade and has been recom-
mended by multiple advisory commit-
tees, most recently in a National Acad-
emies report published a year ago (9)
and a recent letter from the Nuclear
Energy Advisory Committee offering
recommendations to the Department
of Energy (10). We are now in the
Mo-99
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371lybdenum supply chain, and how we
play it will determine whether Ameri-
cans have a continuous supply of Tc-
99m or a crisis in which patients are
unable to obtain essential medical tests.
An interrelated issue is that each of
the 5 major reactors producing Mo-99
uses highly enriched uranium targets,
which contain at minimum 36% and, in
most cases, 93% uranium-235. Highly
enriched uranium is considered by many
experts to be a global nonproliferation
concern (11). The Energy Policy Act of
2005 mandated a National Academy of
Sciences study, due in December 2008,
that is investigating the possibilities for—
and cost-effectiveness of—providing for
the nation’s medical isotope needs from
sources that do not use highly enriched
uranium (12).
Fortunately, there are potential solu-
tions to America’s molybdenum needs.
One would be for governmental sup-
port of domestic low-enrichmentAvailable at: http://frwebgate5.access.
gpo.gov/cgi-bin/PDFgate.cgi?WAISdocIDtion. A research reactor already in place
could be adapted to provide at least
one-half of U.S. Mo-99 demand, al-
though this would require capital to
build a processing facility, which would
cost an estimated $40 million. Most
likely this would necessitate federal
funding, probably through the Depart-
ment of Energy. Such funding, which
is advocated in the Nuclear Energy
Advisory Committee’s letter to the
Secretary of Energy (10), would require
a change in the current language in the
Senate’s proposed 2009 Energy and
Water Development and Related
Agencies Appropriations Act, which
provides for a feasibility study (13) but
not for development of a processing
facility.
Another strong possibility for a do-
mestic molybdenum source, although
likely on a longer timetable, is an effort
in the private sector to develop a novel
type of reactor technology, called annap.edu/openbook.php?record_id11985.
Accessed November 4, 2008.
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turanium dissolved in water and acid
serves as both the reactor’s target and
fuel. An aqueous homogenous reactor
would generate significantly less radio-
active waste than do current processes.
Both of these potential solutions to our
molybdenum needs would use low-
enriched uranium targets for molybde-
num production.
With the cancellation of the MA-
PLE reactor project, it is clear that the
present U.S. Mo-99 supply chain is not
sustainable for the long term, and thus
it is imperative that we explore poten-
tial domestic sources. Our continued
ability to provide the best health care to
our patients lies in the balance.
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